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Abstract
Millions of men, as a result of the natural aging process, injury, illness, and medical therapies, experience a decline in
testosterone levels that necessitate a need for testosterone supplementation therapy (TST). The signs and symptoms
of testosterone decline may occur gradually, and low testosterone levels may be misdiagnosed as other medical
conditions. Over the past two decades, there has been an increase in testing of testosterone levels and the use of
TST. With so many men now on TST, it is essential for health care professionals to know the signs and symptoms, the
causes of testosterone decline, how testosterone deficiency is diagnosed, what pathological changes are associated
with testosterone decline, and the benefits and risks of TST. In addition, health care providers need to be aware of
the various forms of testosterone available as well as the advantages and disadvantages of each. This article provides a
brief overview of testosterone deficiency, TST treatment options and guidelines, and the risks and benefits associated
with of TST.
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More and more men are being placed on Testosterone
supplementation therapy (TST). According to Layton et
al. (2014), lab testing of testosterone levels and the use of
TST have both substantially increased in the United
States since the year 2000. As the number of men taking
TST has increased, it is important for health care professionals to have an understanding of the disease processes
associated with low testosterone levels, the signs and
symptoms of low testosterone, treatment options available, and the risks and benefits of TST. This article provides a brief overview of these topics, beginning with
signs and symptoms associated with low testosterone
levels.

Signs and Symptoms of Testosterone
Deficiency
Many of the symptoms of testosterone deficiency occur
gradually and go unnoticed and are not diagnosed for
years (Salyer, 2013). Signs and symptoms associated
with testosterone deficiency may include reports of
reduced libido, erectile dysfunction, fatigue, lethargy,
moodiness/irritability, depression, sleep disturbance, a
decline in mental function, hot flashes, and decreased
vitality. Visible physical changes in the body may include
decreased muscle mass, increased body fat, hair loss,
breast discomfort/gynecomastia, and loss of bone mineral
density (Bhasin et al., 2010; Gruenewald & Matsumoto,

2003; Salyer, 2013). Other symptoms may include metabolic syndrome, insulin resistance, and atherosclerosis
(Salyer, 2013).
One of the most common reasons for declining testosterone is the aging process. As part of the aging process,
testosterone levels can begin declining as early as the
third decade in life (Strayer & Cabarera, 2013). This
gradual decline in testosterone may be asymptomatic, or
signs and symptoms of low testosterone, if present, may
be attributed to the senescence process. For example,
memory loss and difficulty concentrating may be attributed to aging and not a symptom of low testosterone, as
well as insomnia, irritability, and a depressed mood (de
Melo, Soares, & Baragatti, 2013).

Diagnosing Testosterone Deficiency
A medical diagnosis of testosterone deficiency (also
referred to as androgen deficiency) is based on the measurement of total serum testosterone levels and the presence of signs and symptoms associated with low
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testosterone levels (Bhasin et al., 2010). A total serum
testosterone level below 300 ng/dL is typically used as
the threshold for testosterone deficiency diagnosis. Total
serum testosterone levels are affected by circadian
rhythms, with peak values in the morning. Therefore,
total serum testosterone levels should be assessed using a
morning blood sample. Confirmation of a testosterone
deficiency diagnosis should be based on at least two measures of total serum testosterone (Bhasin et al., 2010).
In confirming a diagnosis of testosterone deficiency, it
is important to also consider the differences between total
serum testosterone and free testosterone levels (also
referred to as bioavailable testosterone levels). Total
serum testosterone levels refer to all (i.e., “total”) testosterone in the blood. Free testosterone levels refer to testosterone that is not bound to sex hormone binding
globulin (SHBG) and is available (i.e., “free”) to interact
with target cells. In men who are symptomatic and have a
total serum testosterone level near the lower limit of normal, it is recommended that free testosterone levels be
check to determine the amount of bioavailable testosterone (Bhasin et al., 2010).
It is important to note that SHBG concentrations
increase as men age, and this increase in SHBG results in
greater binding of testosterone, leaving less available free
testosterone. The combination of both a decrease in testosterone production and decreased availability of free
testosterone is considered a natural part of aging
(Gruenwald & Matsumoto, 2003). TST should not be
routinely offered to all elderly men based on low testosterone levels alone (Bhasin et al., 2010).
Testosterone deficiency can also be classified as primary or secondary hypogonadism. Primary hypogonadism, also referred to a testicular hypogonadism, results
from a failure of the testis to produce normal levels of
testosterone (Bhasin et al., 2010). In primary hypogonadism, total serum testosterone levels will be low, and
serum luteinizing hormone and follicle-stimulating hormone will typically be high (Salyer, 2013). Secondary
hypogonadism is also referred to as pituitary-hypothalamic hypogonadism and results from defects in the functions of the hypothalamus and pituitary gland (Bhasin et
al., 2010). In secondary hypogonadism, serum testosterone levels will be low, and luteinizing hormone and follicle-stimulating hormone levels will be normal or reduced.
In both primary and secondary hypogonadism, sperm
counts are subnormal (Salyer, 2013).

Associated and Secondary
Conditions of Low Testosterone
Low testosterone is often associated with a number of
other health-related conditions. Testosterone deficiency
has been linked to the development depression, obesity,
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diabetes mellitus, sexual dysfunction, development and/
or exacerbation of cardiovascular disease, stroke, problems with bone density, and metabolic syndrome as well
as other adverse health conditions (Ruige, 2011).
While there are ongoing studies and unanswered questions as to whether or not low testosterone levels directly
lead to or contribute to cardiovascular disease, diabetes,
metabolic syndrome, stroke, and other serious health conditions, there is evidence to suggest a link to these conditions with low testosterone levels. Ruige (2011) concludes
that low serum testosterone is associated with obesity and
can contribute to diabetes. Testosterone is bound to SHBG,
and it is associated with high insulin levels and insulin
resistance. An increase in insulin resistance along with
low testosterone is associated with an increase in adipose
tissue, which can lead to obesity in men. Obesity itself has
long been recognized as a leading contributor to cardiovascular disease, diabetes, high blood pressure, and stroke.
Anemia is frequently associated with low testosterone
and type 2 diabetes. Testosterone deficiency has been
independently associated with anemia. Grossmann et al.
(2009) conclude that men with total testosterone level
less than 10nmol/I were more likely to have anemia,
hemoglobin less than 17, and patients with free testosterone levels less than 0.23 nmol/L were twice as likely to
develop anemia.
It is widely agreed that low testosterone and depression are both more common with aging men (Joshi et al.,
2010). However, more research needs to be conducted
before a definite link between low testosterone and
depression in men as part of the aging process can be
established. Joshi et al. (2010) conducted a study of 608
men (65 years and older), with a median age 75.6, and
conclude that free testosterone levels below 170 nmol/L
are associated with depressive symptoms. Joshi et al. also
reported that free testosterone levels below 220 nmol/L
was a good predictor for the onset of depressive
symptoms.
Metabolic syndrome is another condition often associated with low testosterone. Metabolic syndrome refers to
a number of conditions that can lead to increased risk of
developing heart disease, stroke, and diabetes in individuals who have gained weight, especially in the waist area,
or in family members who have diabetes, high blood levels of cholesterol and glucose, and high blood pressure
(Kapoor & Jones, 2008).
Kapoor and Jones (2008) reported that low testosterone levels are a risk factor for the later development of
metabolic syndrome among males. Kapoor and Jones
also reported declining testosterone levels among men
are associated with carotid and aortic atherosclerosis.
Certain medications have also been reported to cause
lower testosterone levels in men. Rubinstein, Carpenter,
and Minkoff (2013) studied 81 men of age 26 to 79 years,
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with a median age of 51 years, who were being treated at
a chronic pain clinic. The men in this study were identified to be five times more likely to have lower testosterone levels if they were being treated with long acting
opioids. None of the men in this study had been previously diagnosed as having low testosterone levels. Based
on the sample in this study, Rubinstein concluded that
53% of all men taking daily opioids could have testosterone deficiency.

Benefits of TST
While men who undergo TST must be monitored closely
for contraindications and side effects, there are measurable benefits to TST. TST for men with low free and total
testosterone levels has been reported to improve energy
level, improve muscle mass, correct erectile dysfunction,
improve libido, and reduce the risk of weight gain (Salyer,
2013). TST has also been reported to improve symptoms
associated with depression and mental function (Salyer,
2013).
TST helps reduce the risk for development of metabolic syndrome, cardiovascular disease, and diabetes
(Salyer, 2013). Kapoor and Jones (2008) conclude that
early interventional TST has a positive effect on visceral
obesity, insulin sensitivity, glycemic control, and lipid
profiles in men that were diagnosed as having low testosterone levels.
Cai et al. (2014) conducted a systematic review aimed
at determining the metabolic impact of TST on men with
low testosterone levels with diabetes mellitus. Using
PubMed and the Cochrane Library, Cai and his colleagues
completed a literature review and meta-analysis using
only randomized controlled trials. Cai et al. reported that
TST reduced fasting plasma glucose levels, serum insulin
levels, and triglyceride levels. While the authors acknowledge that additional larger well designed randomized
controlled trails are needed, the researchers conclude that
TST therapy may improve glycemic control and decrease
triglyceride levels of men with low testosterone levels
and who also have type 2 diabetes.
In a study that examined 1,365 men aged 28 to 87
years with symptomatic testosterone deficiency,
Ramasamy, Fisher, and Schlegel (2012) concluded that
TST improves early detection of prostate cancer. In this
same study, Ramasamy et al. point out that their study
adds to the already existing research that supports TST is
safe despite reports in the literature of risks associated
with TST.

Risks Associated With TST
With any drug, hormone, or other medical treatment, there
is always the possibility of undesired and unintended
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outcomes. For TST, there are many potential side effects.
Some of the negative effects associated with TST, especially with long-term treatment, can be life threatening.
There is also controversy associated with the use of
testosterone with certain patient populations. In men
who have known coronary artery disease, TST may
need to be used with caution. Vigen et al. (2013) reported
in a retrospective cohort study of 8,709 veterans with
testosterone levels lower than 300 ng/dL, and who also
had a diagnosis of coronary artery disease, that those
placed on TST had a greater risk of an adverse outcome
than those not receiving TST. Adverse outcomes
included myocardial infarctions, stroke, and death. An
absolute risk difference of 5.8% for an adverse outcome
was found in men receiving TST compared with men
not on TST.
TST and its impact on the health of the prostate and its
impact on the prognosis of patients who have been diagnosed with prostate cancer are very controversial.
Ramasamy et al. (2012) point out that since prostate cancer is known to be androgen dependent, there is concern
that undetected tumors may progress into larger tumors
as a result of TST. Ramasamy et al. conclude that while
more clinical trials are needed, there does not appear to be
a relationship between prostate cancer development with
the use of TST. Furthermore, there does not appear to be
a link between TST and advancing prostate disease
(Feneley & Carruthers, 2012).

Forms of TST
There are a number of options to choose from regarding
the forms of TST depending on the patient needs, preferences, and physician recommendation. One of the most
common and inexpensive is intramuscular injection.
While injections are usually only administered once a
month and patients can learn to administer the injection
themselves, injections can be painful and cause soreness
and bruising. There can also be moderate swings in testosterone levels associated with the injection form
(McGill, Shoskes, & Sabanegh, 2012).
TST can also be administered transdermal using
patches, gels, or liquids. Transdermal forms of therapy
provide a more sustained therapeutic benefit. While
more comfortable method of administration, these gels,
ointments, or patches must be administered daily. Patch
sites must be rotated. Patches sometimes lead to dermatology disorders and cannot be worn in water. Care must
be made not to come in contact with children and women
who are pregnant or of childbearing age. Hands must be
washed, and areas applied must be covered (McGill et
al., 2012).
Other forms of TST include subcutaneously implanted
slow release pellets in the buttock. Approximately 8 to 14
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pellets are inserted every 3 to 6 months. Advantages
include slower release and more sustained therapeutic
benefit and less frequent treatment cycles. Disadvantages
of this relatively new form of treatment include invasive
procedure, risk of infection, and extrusion of pellets in a
small percentage of patients.
Buccal TST is also an option; however, this method of
replacement therapy is frequently associated with gum
disease and never became a popular choice of patients or
practitioners. Oral forms of testosterone are strongly
Testosterone Supplement Options.
Route
Methyltestosterone
(Android)

Dosage

Side effects

10 to 50 mg oral
daily

Hepatic
effects, lower
androgen
response
Hepatic
effects, lower
response
Oral irritation

Fluoxymesterone
(Halotestin)

5 to 20 mg oral
daily

Testosterone buccal
(Striant)
Testosterone patch
(Androderm)
Testosterone
transdermal
(Testoderm)
Testosterone
cypionate (DepoTestosterone)

30 mg applied to
gums twice daily
Applied to skin
daily
Patch applied to
scrotum daily

Testosterone
enanthate
(Delatestryl)
Testosterone 1% gel
(AndroGel)
Testosterone pellets
(Testopel)

Site reaction
Site reaction,
transfer to
partner
Urticaria, site
reactions

50 to 400 mg
intramuscularly
every 2 to 4
weeks
50 to 400 mg
Site reaction
intramuscularly
every 2 to 4
weeks
5 gm topically once Site reaction,
daily
transfer to
partner
150 to 450 mg
Site pain and
implanted
inflammation
subcutaneously
every 3 to 6
months

Source. McGill et al. (2012).

associated with hepatic disease and are not used in the
United States (McGill et al., 2012).

Conclusion
Many men because of aging, illness, or medical treatment experience a decline in testosterone level and as a
result are placed on TST. Health care professionals must
understand the signs and symptoms of testosterone deficiency, that these signs and symptoms often occur gradually over time, sometimes are not diagnosed timely,

and can be similar to other associated medical conditions. This article provided a brief review of the signs
and symptoms, the causes of testosterone decline, diagnosis of testosterone deficiency, pathological changes
that occur with testosterone decline, advantages of TST,
the consequences of TST, and the secondary and associated other health conditions related to low testosterone
levels. The various forms of TST available as well as the
advantages and disadvantages of each were also discussed. With the number of men on TST dramatically
increasing, it is critical that health care professionals
understand the totality of testosterone deficiency and
treatment.
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